Overview Performance Dividends Peer Group Options

(HOTH) Hoth Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US44148G1058

HOTH: Skin Treatment, Cancer Therapy, Brain Injury, Alzheimers, Asthma

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, is dedicated to addressing unmet medical needs through innovative therapies. Their pipeline includes HT-001, a topical treatment in Phase II trials for skin disorders linked to tyrosine kinase inhibitor therapy; HT-KIT, targeting mast-cell derived cancers and anaphylaxis; HT-TBI for traumatic brain injury and ischemic stroke; HT-ALZ for Alzheimers and neuroinflammatory diseases; HT-004, an inhalational therapy for asthma and allergies; and HT-003, which treats acne, psoriasis, and inflammatory bowel diseases. Additionally, their BioLexa Platform is in Phase I for eczema, and HT-005 is under development for lupus.

Hoth has established strategic partnerships with institutions like George Washington University and Weill Cornell Medicine, enhancing their research capabilities. Their collaborations underscore a commitment to advancing therapeutic solutions through academic and industry alliances, potentially accelerating drug development.

Based on the stocks current price of $1.09, with SMA 20 at $1.05, SMA 50 at $1.18, and SMA 200 at $0.96, the stock shows potential bullish signals if the SMA 20 crosses above the SMA 50. The ATR of 0.25 indicates moderate volatility, suggesting price fluctuations within a $0.25 range over the next quarter. With a market cap of $11.97M and P/B ratio of 1.66, Hoth is positioned as a high-risk, high-reward investment. The absence of P/E and P/S data reflects the companys pre-revenue stage. Positive clinical trial results could significantly boost the stock price, while adverse outcomes may lead to a decline, given the speculative nature of biotech investments.

Additional Sources for HOTH Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

HOTH Stock Overview

Market Cap in USD 14m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2019-02-15

HOTH Stock Ratings

Growth 5y -84.5%
Fundamental -
Dividend 0.0%
Rel. Strength Industry -6.76
Analysts 5/5
Fair Price Momentum 0.56 USD
Fair Price DCF -

HOTH Dividends

No Dividends Paid

HOTH Growth Ratios

Growth Correlation 3m 26.8%
Growth Correlation 12m -23.3%
Growth Correlation 5y -98.3%
CAGR 5y -58.19%
CAGR/Max DD 5y -0.59
Sharpe Ratio 12m -0.99
Alpha 4.48
Beta -2.25
Volatility 91.85%
Current Volume 263.7k
Average Volume 20d 324.4k
What is the price of HOTH stocks?
As of March 15, 2025, the stock is trading at USD 1.11 with a total of 263,740 shares traded.
Over the past week, the price has changed by +1.83%, over one month by -1.77%, over three months by +37.04% and over the past year by -5.93%.
Is Hoth Therapeutics a good stock to buy?
No, based on ValueRay Analyses, Hoth Therapeutics (NASDAQ:HOTH) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -84.47 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HOTH as of March 2025 is 0.56. This means that HOTH is currently overvalued and has a potential downside of -49.55%.
Is HOTH a buy, sell or hold?
Hoth Therapeutics has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy HOTH.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for HOTH stock price target?
According to ValueRays Forecast Model, HOTH Hoth Therapeutics will be worth about 0.6 in March 2026. The stock is currently trading at 1.11. This means that the stock has a potential downside of -45.95%.
Issuer Forecast Upside
Wallstreet Target Price 4.5 305.4%
Analysts Target Price 4.5 305.4%
ValueRay Target Price 0.6 -45.9%